Deletion of ER-retention Motif on SARS-CoV-2 Spike Protein Reduces Cell Hybrid During Cell-cell Fusion

The novel SARS-CoV-2 has rapidly develop into a world pandemic for the reason that first reported case in December 2019, with the virus infecting tens of millions of individuals to this point. The spike (S) protein of the SARS-CoV-2 virus performs a key function in binding to angiotensin-converting enzyme 2 (ACE2), a number cell receptor for SARS-CoV-2. S proteins which are expressed on the cell membrane can provoke receptor-dependent syncytia formation that’s related to intensive tissue harm. Formation of syncytia have been beforehand noticed in cells contaminated with varied different viruses (e.g., HIV, Ebola, Influenza, and Herpesviruses).

Nevertheless, this phenomenon isn’t properly documented and the mechanisms regulating the formation of those syncytia by SARS-CoV-2 aren’t totally understood. On this research, we investigated the chance that cell fusion occasions mediated by the S protein of SARS-CoV-2 and ACE2 interplay can happen in several human cell strains that mimic totally different tissue origins. These cell strains have been stably transduced with both wild-type (WT-S) S protein or a mutated variant the place the ER-retention motif was eliminated (Δ19-S), or human ACE2 vectors.

Totally different co-culture mixtures of spike-expressing 293T, A549, Ok562, and SK-Hep1 cells with hACE2-expressing cells revealed cell hybrid fusion. Nevertheless, solely sure cells expressing S protein can kind syncytial buildings as this phenomenon can’t be noticed in all co-culture mixtures. Thus, SARS-CoV-2 mediated cell-cell fusion represents a cell type-dependent course of which could depend on a distinct set of parameters. Just lately, the Δ19-S variant is being broadly used to extend SARS-CoV-2 pseudovirus manufacturing for in vitro assays.

Comparability of cell fusion occurring by way of Δ19-S expressing cells exhibits faulty nuclear fusion and syncytia formation in comparison with WT-S. This distinction between the Δ19-S variant and WT-S protein might have downstream implications for research that make the most of pseudovirus-based entry assays. Moreover, this research counsel that spike protein expressed by vaccines might have an effect on totally different ACE2-expressing host cells after SARS-CoV-2 vaccine administration. The long-term results of those vaccines must be monitored rigorously.

Molecular and Mobile Mechanisms of Respiratory Syncytial Viral An infection: Utilizing Murine Fashions to Perceive Human Pathology

Respiratory syncytial virus (RSV) causes extreme pathology of the decrease respiratory tract in infants, immunocompromised individuals, and aged. Regardless of a long time of analysis, there isn’t any licensed vaccine in opposition to RSV, and plenty of therapeutic medicine are nonetheless underneath improvement. Detailed understanding of molecular and mobile mechanisms of the RSV an infection pathology can speed up the event of efficacious therapy. Present research on the RSV pathogenesis are primarily based on the evaluation of biopsies from the contaminated sufferers; nonetheless deeper understanding of molecular and mobile mechanisms of the RSV pathology could possibly be achieved utilizing animal fashions.

Mice are essentially the most typically used mannequin for RSV an infection as a result of they exhibit manifestations much like these noticed in people (bronchial obstruction, mucous hypersecretion, and pulmonary irritation mediated by lymphocytes, macrophages, and neutrophils). Moreover, using mice is economically possible, and plenty of molecular instruments can be found for learning RSV an infection pathogenesis on the molecular and mobile ranges. This evaluation summarizes new information on the pathogenesis of RSV an infection obtained in mouse fashions, which demonstrated the function of T cells in each the antiviral protection and the event of lung immunopathology.

T cells not solely get rid of the contaminated cells, but additionally produce vital quantities of the proinflammatory cytokines TNFα and IFNγ. Just lately, a brand new subset of tissue-resident reminiscence T cells (TRM) was recognized that present a powerful antiviral protection with out induction of lung immunopathology. These cells accumulate within the lungs after native somewhat than systemic administration of RSV antigens, which suggests new approaches to vaccination. The research in mouse fashions have revealed a minor function of interferons within the anti-RSV safety, as RSV possesses mechanisms to flee the antiviral motion of kind I and III interferons, which can clarify the low efficacy of interferon-containing medicine.

Utilizing knockout mice, a major breakthrough has been achieved in understanding the function of many pro-inflammatory cytokines in lung immunopathology. It was discovered that along with TNFα and IFNγ, the cytokines IL-4, IL-5, IL-13, IL-17A, IL-33, and TSLP mediate the main manifestations of the RSV pathogenesis, equivalent to bronchial obstruction, mucus hyperproduction, and lung infiltration by pro-inflammatory cells, whereas IL-6, IL-10, and IL-27 exhibit the anti-inflammatory impact. Regardless of vital variations between the mouse and human immune methods, mouse fashions have made a major contribution to the understanding of molecular and mobile mechanisms of the pathology of human RSV an infection.

Deletion of ER-retention Motif on SARS-CoV-2 Spike Protein Reduces Cell Hybrid During Cell-cell Fusion

Competitors between RSV and influenza: Limits of modelling inference from surveillance information

Respiratory Syncytial Virus (RSV) and Influenza trigger a big burden of illness. Proof of their interplay by way of short-term cross-protection implies that prevention of 1 may inadvertently result in a rise within the burden of the opposite. Nevertheless, proof for the general public well being influence of such interplay is sparse and largely derives from ecological analyses of peak shifts in surveillance information. To check the robustness of estimates of interplay parameters between RSV and Influenza from surveillance information we carried out a simulation and back-inference research.

pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-520A-KIT 1 kit
EUR 1141

Human Glucose concentration(Glucose concentration) ELISA Kit

QY-E05365 96T
EUR 433.2

pPACK-SPIKE D614G Combo Kit, includes Cat# CVD19-530A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-550A-KIT 1 kit
EUR 1141

pPACK-SPIKE N501Y Combo Kit, includes Cat# CVD19-560A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-575A-KIT 1 kit
EUR 1141

pPACK-SPIKE Alpha Combo Kit, includes Cat# CVD19-590A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-599A-KIT 1 kit
EUR 1141

pPACK-SPIKE Gamma Combo Kit, includes Cat# CVD19-630A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-639A-KIT 1 kit
EUR 1141

pPACK-SPIKE Beta Combo Kit, includes Cat# CVD19-640A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-649A-KIT 1 kit
EUR 1141

pPACK-SPIKE Delta Combo Kit, includes Cat# CVD19-650A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-659A-KIT 1 kit
EUR 1141

pPACK-SPIKE Omicron Combo Kit, includes Cat# CVD19-660A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-669A-KIT 1 kit
EUR 1162

pPACK-SPIKE B.1.429 Combo Kit, includes Cat# CVD19-610A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-619A-KIT 1 kit
EUR 1141

pPACK-SPIKE B.1.525 Combo Kit, includes Cat# CVD19-620A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-629A-KIT 1 kit
EUR 1141

pPACK-SPIKE B.1.351 RBD Mutations Combo Kit, includes Cat# CVD19-580A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-589A-KIT 1 kit
EUR 1141

pPACK-SPIKE B.1.351 S1 Mutations Combo Kit, includes Cat# CVD19-600A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)

CVD19-609A-KIT 1 kit
EUR 1141

ETHANOL, 70% CONCENTRATION

IB15727 10L
EUR 210.13
Description: BOX W/SPIGOT (HAZ)

ddATP - high concentration

NU-271L 5 x 10µl
EUR 146.8

ddATP - high concentration

NU-271S 10µl
EUR 51.9

ddCTP - high concentration

NU-272L 5 x 10µl
EUR 146.8

ddCTP - high concentration

NU-272S 10µl
EUR 51.9

ddGTP - high concentration

NU-273L 5 x 10µl
EUR 146.8

ddGTP - high concentration

NU-273S 10µl
EUR 51.9

ddTTP - high concentration

NU-274L 5 x 10µl
EUR 146.8

ddTTP - high concentration

NU-274S 10µl
EUR 51.9

pSET152- Low concentration

PVT11339 2 ug
EUR 444

pSET152- high concentration

PVT11338 2 ug
EUR 444

TEV Protease (High Concentration)

LE-002L 100000Units
EUR 5271.8

TEV Protease (High Concentration)

LE-002S 10000Units
EUR 691.2

MS BASAL SALT CONCENTRATION (20x)

M576 1000ML
EUR 25.31

Denhardt's solution, 100x Concentrate

D0062 25ml
EUR 82.97

Wash Solution Concentrate (50X)

WSC999 1000 ml
EUR 79.73

Wash Solution Concentrate (HPE)

DS0024-125ML 1 unit
EUR 141.01
Description: Wash Solution Concentrate (HPE)

Wash Solution Concentrate (HPE)

DS0024-250ML 1 unit
EUR 280.84
Description: Wash Solution Concentrate (HPE)

Prewash Solution Concentrate (PW)

DS0011-400ML 1 unit
EUR 240.82
Description: Prewash Solution Concentrate (PW)

BD High Concentration Laminin - EACH

354259 EACH
EUR 849.15

AvaI -HC unit: 330, High Concentration

YRAVA1-HC 1 vial Ask for price

SacI -HC unit: 1500, High Concentration

YRSAC1-HC 1 vial Ask for price

Minimal Inhibitory Concentration Kit

K195-2500 each
EUR 836.4

Minimal Inhibitory Concentration Kit

K195-500 each
EUR 574.8

pRK2013- 1 (Low concentration) Plasmid

PVT5705 2 ug
EUR 390

Biotin-11-UTP - high concentration

NU-821-BIOX-HC 30µl
EUR 1480.4

Kpn I -HC unit: 5000, High Concentration

YRKPN1-HC 1 vial Ask for price

Msp I -HC unit: 1400, High Concentration

YRMSP1-HC 1 vial Ask for price

Nco I -HC unit: 400, High Concentration

YRNCO1-HC 1 vial Ask for price

Pst I -HC unit: 12000, High Concentration

YRPST1-HC 1 vial Ask for price

Pvu II -HC unit: 2000, High Concentration

YRPVU2-HC 1 vial Ask for price

Rsa I -HC unit: 800, High Concentration

YRRSA1-HC 1 vial Ask for price

Sal I -HC unit: 2200, High Concentration

YRSAL1-HC 1 vial Ask for price

Sma I -HC unit: 1500, High Concentration

YRSMA1-HC 1 vial Ask for price

Taq I -HC unit: 410, High Concentration

YRTAQ1-HC 1 vial Ask for price

Xba I -HC unit: 3000, High Concentration

YRXBA1-HC 1 vial Ask for price

Xho I -HC unit: 5000, High Concentration

YRXHO1-HC 1 vial Ask for price

High Concentration Acid Surrogate - 1ML

CLP90-75SA 1ML
EUR 259.2

pRK2013- 2 (High concentration) Plasmid

PVT5706 2 ug
EUR 390

Hi-SYBr Master Mix (Concentration 2X)

MBT074-0.5ML 1 unit
EUR 54.43
Description: Hi-SYBr Master Mix (Concentration 2X)

Hi-SYBr Master Mix (Concentration 2X)

MBT074-1ML 1 unit
EUR 104.64
Description: Hi-SYBr Master Mix (Concentration 2X)

Hi-SYBr Master Mix (Concentration 2X)

MBT074-5ML 1 unit
EUR 418.52
Description: Hi-SYBr Master Mix (Concentration 2X)

Dra I-HC unit: 3500, High Concentration

YRDRA1-HC 1 vial Ask for price

EcoR I -HC unit: 12000, High Concentration

YRECOR1-HC 1 vial Ask for price

X-Gal Solution, 40 mg/ml concentrate

X0321-005 5X1ml
EUR 138

X-Gal Solution, 40 mg/ml concentrate

X0321-020 20ml
EUR 162

BamH I-HC unit: 12000, High Concentration

YRBAMH1-HC 1 vial Ask for price

Bgl II-HC unit: 2500, High Concentration

YRBGL2-HC 1 vial Ask for price

EcoR V-HC unit: 2000, High Concentration

YRECOR5-HC 1 vial Ask for price

Hind III -HC unit: 12000, High Concentration

YRHIND3-HC 1 vial Ask for price

Hinf I-HC unit: 2000, High Concentration

YRHINF1-HC 1 vial Ask for price

Sperm Concentration Rapid Test Cassette

OSC-902H 1 Test
EUR 1.2

ViaCheck™ Concentration Control (0.5 × 106)

VC50N-20 20 mL
EUR 216
Description: HS Code : 38220000

ViaCheck Concentration Control 1 x 106

VC60N-20 20 ml
EUR 251.33
Description: ViaCheck Concentration Control 1 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers 

ViaCheck Concentration Control 4 x 106

VC70N-20 20 ml
EUR 367.48
Description: ViaCheck Concentration Control 4 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers 

ViaCheck Concentration Control 8 x 106

VC80N-20 20 ml
EUR 410.53
Description: ViaCheck Concentration Control 8 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers 

Presto™ Plasmid DNA Concentration Kit

PC0002 each
EUR 3

Presto™ Plasmid DNA Concentration Kit

PC0250 each
EUR 40

Presto™ Plasmid DNA Concentration Kit

PC0251 each
EUR 30

Presto™ Plasmid DNA Concentration Kit

PC0500 each
EUR 72.6

Presto™ Plasmid DNA Concentration Kit

PC0501 each
EUR 53.5

Presto™ Plasmid DNA Concentration Kit

PC1000 each
EUR 128

Presto™ Plasmid DNA Concentration Kit

PC1001 each
EUR 87

UPCK™ Urine Protein Concentration Kit

UPCK-10 10 preps
EUR 795

UPCK™ Urine Protein Concentration Kit

UPCK-25 25 preps
EUR 1143.6
Description: Urine Protein Enrichment Kit

UPCK™ Urine Protein Concentration Kit

UPCK-50 50 preps Ask for price

BssH II-HC unit: 200, High Concentration

YRBSSH2-HC 1 vial Ask for price

BstE II-HC unit: 1300, High Concentration

YRBSTE2-HC 1 vial Ask for price

EcoT38 I -HC unit: 900, High Concentration

YRECOT38-HC 1 vial Ask for price

Hae III-HC unit: 3400, High Concentration

YRHAE3-HC 1 vial Ask for price

Hinc II-HC unit: 500, High Concentration

YRHINC2-HC 1 vial Ask for price

Cas9 Nuclease Protein (High Concentration)

K108 40 µg (250pmol) Volume: 25µL
EUR 80
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants.

Lentivirus Concentrator

LV-CONC one kit
EUR 276.5
Description: lentivirus concentration kit

Chloride Std Solution Concentrate - 100ML

5000900C 100ML
EUR 203.85

Concentrating Solution for Sirius Red Total Collagen Detection Other

90626 50 ml
EUR 14
Description: Concentrating Solution for Sirius Red Total Collagen Detection Kit

saCas9 Nuclease Protein (High Concentration)

K144 32.5 µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT).

Citrate concentrated buffer, 4% solution

GB4634-100 100
EUR 45.2

Citrate concentrated buffer, 4% solution

GB4634-250 250
EUR 90.4

Citrate concentrated buffer, 4% solution

GB4634-500 500
EUR 150.7

ViaCheck™ Concentration Control 1 x 106

24627-20 20ml
EUR 216

ViaCheck™ Concentration Control 4 x 106

24628-20 20ml
EUR 329

ViaCheck™ Concentration Control 8 x 106

24629-20 20ml
EUR 372

Cas9 Null Mutant Protein (High Concentration)

K140 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants.

Cas9 Nuclease NLS Protein (High Concentration)

K130 40 µg (250pmol) Volume: 25µL
EUR 80
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

Cas9 Nickase D10A Protein (High Concentration)

K132 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants.

Cas9 Nickase H840A Protein (High Concentration)

K136 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants.

saCas9 Null Mutant Protein (High Concentration)

K146 32.5 µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT).

Myoglobin Concentration ELISA Quantitation Kit

GWB-E1E945 ELISA_Kits Ask for price

dNTP SET, Concentration: 100mM, 4x1ml set of dNTP consisting 4 separate tubes (4x1ml) each with 100mM concentration of dATP, dGTP, dCTP, and dTTP.

2013SET each
EUR 361.42

AAVancedTM Concentration Reagent (100 ml aliquot)

AAV100A-1 100 ml
EUR 462

AAVancedTM Concentration Reagent (250 ml aliquot)

AAV110A-1 250 ml
EUR 928

asCpf1 Nuclease NLS Protein (High Concentration)

K188 380 μg (2.5 nmol) Volume: 250µL
EUR 365
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases. ;
  • Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
  • Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
  • Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
  • Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
    • asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).

saCas9 Nuclease NLS Protein (High Concentration)

K189 32.5 µg (250pmol) Volume: 50µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

fnCpf1 Nuclease NLS Protein (High Concentration)

K187 380 μg (2.5 nmol) Volume: 250µL
EUR 365
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.;
  • Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
  • Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
  • Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
  • Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
    • fnCpf1 is from the bacteria Francisella novicida. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by fnCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).

asCpf1 Nuclease NLS Protein (High Concentration)

K088 38 μg (250 pmol) Volume: 25µL
EUR 75
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.;
  • Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
  • Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
  • Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
  • Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
    • asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).

saCas9 Nuclease NLS Protein (High Concentration)

K089 6.5 µg (50pmol) Volume: 50µL
EUR 55
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

96 Well Plate RNA Cleanup and Concentration Kit

BRC1251 2xPlates, 192prep
EUR 300.37

Cas9 Null Mutant NLS Protein (High Concentration)

K142 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Null Mutant NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

ViaCheck™ Concentration Control, 0.5e+6 beads/mL

26409-20 20ml
EUR 216

Cas9 Nuclease GFP NLS Protein (High Concentration)

K148 47µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR). ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 Nuclease NLS to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 Nuclease-GFP can also be used for FACS applications and screening. Cas9 Nuclease-GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. Our Cas9-GFP proteins have the Enhanced green fluorescent protein (eGFP).

Cas9 Nickase D10A NLS Protein (High Concentration)

K134 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 D10A Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

EPA CLP Volatiles Standards Low Concentration - 1ML

CLPV-LC-A 1ML
EUR 121.5

Cas9 Nickase H840A NLS Protein (High Concentration)

K138 40 µg (250pmol) Volume: 25µL
EUR 135
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 H840 Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 H840 Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

saCas9 Null Mutant NLS Protein (High Concentration)

K147 32.5 µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;; The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 NLS Null Mutant contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

VOC Std 14 Comp Mix Mixed Concentration in MeOH - 1ML

REVOC0183 1ML
EUR 586.05

Cas9 Null Mutant GFP NLS Protein (High Concentration)

K186 47µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression. ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 Null Mutant GFP can also be used for FACS applications and screening. Cas9 D10A Null Mutant GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

Cas9 D10A Nickase GFP NLS Protein (High Concentration)

K149 47µg (250pmol) Volume: 25µL
EUR 155
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements. ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 D10A Nickase-GFP can also be used for FACS applications and screening. Cas9 D10A Nickase -GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

EZ-10 Spin Column RNA Cleanup and Concentration Kit

BS91315 50Preps
EUR 119.38

Scott's Tap Water Substitute Concentrate, 10X solution

GE4184-1 1
EUR 30.1

Scott's Tap Water Substitute Concentrate, 10X solution

GE4184-2500 2500
EUR 60.3

Matrigel basement matrix high concentration 10ml - EACH

354248 EACH
EUR 1051.65

ViaCheck™ Concentration Control (0.5 × 106) SingleShots™

VC50NSS-25 25 vials
EUR 266
Description: HS Code : 38220000

ViaCheck™ Concentration Control (0.5 × 106) SingleShots™

VC50NSS-75 75 vials
EUR 716
Description: HS Code : 38220000

ViaCheck™ Concentration Control (1 × 106) SingleShots™

VC60NSS-25 25 vials
EUR 266
Description: HS Code : 38220000

ViaCheck™ Concentration Control (1 × 106) SingleShots™

VC60NSS-75 75 vials
EUR 714
Description: HS Code : 38220000

ViaCheck™ Concentration Control (4 × 106) SingleShots™

VC70NSS-25 25 vials
EUR 388
Description: HS Code : 38220000

ViaCheck™ Concentration Control (4 × 106) SingleShots™

VC70NSS-75 75 vials
EUR 1047
Description: HS Code : 38220000

ViaCheck™ Concentration Control (8 × 106) SingleShots™

VC80NSS-25 25 vials
EUR 423
Description: HS Code : 38220000

ViaCheck™ Concentration Control (8 × 106) SingleShots™

VC80NSS-75 75 vials
EUR 1143
Description: HS Code : 38220000

We developed a two-pathogen interplay mannequin, parameterised to simulate RSV and Influenza epidemiology within the UK. Utilizing the an infection mannequin together with a surveillance-like stochastic remark course of we generated a variety of doable RSV and Influenza trajectories after which used Markov Chain Monte Carlo (MCMC) strategies to back-infer parameters together with these describing competitors.

Leave a Reply

Your email address will not be published. Required fields are marked *